Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16965781 | 1.00 | DPP4 (0.41) | DPP4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL1152738 | 1.00 | DPP4 (0.41) | DPP4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL4556659 | 0.96 | LMNA (0.41) | DPP4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL8622210 | 0.96 | LMNA (0.41) | DPP4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL1153684 | 0.96 | LMNA (0.41) | DPP4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL7101907 | 0.94 | CHRM2 (0.40) | DPP4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL7105607 | 0.94 | CHRM2 (0.40) | DPP4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL1153253 | 0.94 | CHRM2 (0.40) | DPP4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL4441548 | 0.94 | CHRM2 (0.40) | DPP4F2OPRM1OPRD1OPRK1 | |
| SCHEMBL18793693 | 0.91 | DPP4 (0.44) | DPP4F2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900223-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9226922-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| CN-100436406-C | Process for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL CO (JP) | 2008-11-26 | — | — | CN | disclosed |
| CN-100408553-C | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate of the same | SUMITOMO CHEMICAL CO (JP) | 2008-08-06 | — | — | CN | disclosed |
| CN-1898193-A | Method for producing optically active bisamidealcohol compound | SUMITOMO CHEMICAL CO (JP) | 2007-01-17 | — | — | CN | disclosed |
| CN-1898196-A | Process for producing optically active cycloalkylidenebisoxazoline compound and intermediate of the compound | SUMITOMO CHEMICAL CO (JP) | 2007-01-17 | — | — | CN | disclosed |
| EP-1156054-B1 | DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-0942010-B1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymer | SUMITOMO CHEMICAL CO (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-6500909-B2 | CONTAINING NICKEL, PALLADIUM, RHODIUM, RUTHENIUM, OR COBALT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-6495533-B1 | TUMOR NECROSIS FACTOR INHIBITORS; RHEUMATOID ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE, HEPATITIS, SEPSIS, HEMORRHAGIC SHOCK, MULTIPLE SCLEROSIS, CEREBRAL INFARCTION, DIABETES, INTERSTITIAL PNEUMONIA, PAIN, HIV | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1156054-A1 | DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-20010027162-A1 | Transition metal compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and process for producing olefinic polymer | HIRAHATA WATARU (JP) | 2001-10-04 | — | — | US | disclosed |
| US-6242377-B1 | POLYMERIZATION IN PRESENCE OF BISOXAZOLINE WITH NICKEL, COBALT, PALLADIUM, RHODIUM, RUTHENIUM, ALUMINUM AND BORON COMPLEXES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-0942010-A1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | DPP4 2478/4885F2 4466/4885OPRM1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.